Fig. 5
MOF@FM as a vaccine for tumor prevention. a In vivo fluorescence imaging at the indicated time points after the subcutaneous injection of samples. b Ex vivo fluorescent images of lymph node and spleen at 36 h after subcutaneous injection. c Illustration of the experiment design. Healthy mice were immunized twice in every week by subcutaneous injection and tumor challenge at 7 d after the last immunization. d Percentage of tumor-free mice after tumor challenge. e Photos of harvested tumors at 36 d after tumor challenge. f Levels of secreted IFN-γ in mice serum measured by ELISA kit. The mean values and s.d. were presented and measurements were taken from distinct samples (one-way ANOVA; ns not significant, ***p < 0.001, n = 3). g Levels of secreted IL-6 in mice serum measured by ELISA kit. The mean values and s.d. were presented and measurements were taken from distinct samples (one-way ANOVA; ns: not significant, ***p < 0.001, n = 3). h Flow cytometric quantification of CD3 and CD8 expressed by splenic lymphocytes at 7th day after twice immunizations. i Immunofluorescence observation over CD8 in the draining lymph node; Scale bar = 50 μm. Source data are provided as a Source Data file
